Table 3 Post-index healthcare utilization while persistent on antifibrotics
All Patients | Pirfenidone | Nintedanib | P Value1 | |
|---|---|---|---|---|
N = 1248 | N = 697 | N = 551 | ||
Follow-Up | ||||
Days of follow-up after index date, mean (SD) | 247.0 (243.7) | 260.7 (251.1) | 229.6 (233.0) | 0.025 |
All-cause utilization | ||||
Inpatient hospitalization2, n (%) | 271 (21.7) | 172 (24.7) | 99 (18.0) | 0.004 |
Inpatient hospitalizations PPPM, mean (SD) | 0.06 (0.17) | 0.06 (0.18) | 0.05 (0.16) | 0.208 |
Length of stay, mean (SD), days | 5.0 (4.1) | 4.8 (3.4) | 5.4 (5.1) | 0.239 |
Median | 4 | 4 | 4 | |
Any outpatient visit, n (%) | 1195 (95.8) | 666 (95.6) | 529 (96.0) | 0.692 |
Emergency department visit | 308 (24.7) | 174 (25.0) | 134 (24.3) | 0.793 |
Visits PPPM, mean (SD) | 0.07 (0.23) | 0.07 (0.20) | 0.08 (0.26) | 0.163 |
Physician office visit | 1092 (87.5) | 613 (87.9) | 479 (86.9) | 0.590 |
Visits PPPM, mean (SD) | 1.2 (1.0) | 1.2 (1.0) | 1.2 (1.0) | 0.724 |
Pharmacy, n (%) | 1248 (100.0) | 697 (100.0) | 551 (100.0) | 1.000 |
Medication claims PPPM, mean (SD) | 4.3 (2.6) | 4.2 (2.5) | 4.3 (2.7) | 0.335 |
Respiratory-related utilization | ||||
Inpatient hospitalization2, n (%) | 146 (11.7) | 97 (13.9) | 49 (8.9) | 0.006 |
Inpatient hospitalizations PPPM, mean (SD) | 0.03 (0.13) | 0.03 (0.14) | 0.02 (0.11) | 0.166 |
Length of stay, mean (SD), days | 5.3 (5.4) | 4.6 (3.2) | 6.5 (8.1) | 0.052 |
Median | 4 | 4 | 4 | |
Any outpatient visit, n (%) | 1147 (91.9) | 640 (91.8) | 507 (92.0) | 0.901 |
Emergency department visit | 173 (13.9) | 101 (14.5) | 72 (13.1) | 0.470 |
Visits PPPM, mean (SD) | 0.04 (0.14) | 0.03 (0.13) | 0.04 (0.16) | 0.196 |
Physician office visit | 1025 (82.1) | 577 (82.8) | 448 (81.3) | 0.499 |
Visits PPPM, mean (SD) | 0.68 (0.63) | 0.68 (0.65) | 0.67 (0.60) | 0.913 |
Pharmacy, n (%) | 1248 (100.0) | 697 (100.0) | 551 (100.0) | 1.000 |
Medication claims PPPM, mean (SD) | 1.4 (0.7) | 1.4 (0.7) | 1.5 (0.8) | 0.026 |